SymBio Pharmaceuticals Limited (SYMQY)

Market Cap	33.82M -35.0%
Revenue (ttm)	8.03M -39.7%
Net Income	-36.83M
EPS	-0.67
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Open	0.6603
Previous Close	0.5579
Day's Range	0.5579 - 0.6603
52-Week Range	0.5579 - 1.3100
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 91
• Stock Exchange: OTCMKTS
• Ticker Symbol: SYMQY

Financial Performance

In 2025, SymBio Pharmaceuticals's revenue was 1.31 billion, a decrease of -46.70% compared to the previous year's 2.45 billion. Losses were -4.78 billion, 24.6% more than in 2024.

Financial numbers in JPY